Navigation Links
Micromet to Host Conference Call and Webcast to Discuss Blinatumomab Data Presented at EHA on June 8, 2009
Date:6/2/2009

eatment of patients with acute lymphoblastic leukemia (ALL), and in a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma (NHL). A second BiTE antibody, MT110, is in a phase 1 clinical trial for the treatment of patients with solid tumors. MT110 binds to the epithelial cell adhesion molecule, or EpCAM, which is overexpressed in many solid tumors. Micromet's human monoclonal antibody adecatumumab (MT201) also binds to EpCAM and is being developed under a collaboration with Merck Serono. Adecatumomab is in a phase 2 clinical trial in colorectal carcinoma patients after complete resection of liver metastases, and a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. Micromet's monoclonal antibody MT293, also known as TRC093, is licensed to TRACON Pharmaceuticals, Inc., and is in a phase 1 clinical trial for the treatment of patients with cancer.

In addition, Micromet has established a collaboration with Nycomed for the development and commercialization of MT203, a human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, or multiple sclerosis. Nycomed has filed a clinical trial application and is expected to commence a phase 1 clinical trial of MT203 in the first half of 2009. Micromet's licensee Morphotek, a wholly-owned subsidiary of Eisai, is also expected to initiate a first phase 1 clinical trial with Micromet's glycolipid-binding human antibody MT228 for the treatment of melanoma. Micromet also has entered into an option, collaboration and license agreement with Bayer Schering Pharma AG under which Bayer Schering Pharma was granted an exclusive option to license a specified BiTE antibody against an undisclosed solid tumor target.

Micromet's pr
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Micromet Presents Update at ASCO 2009 on a Phase 1b Combination Study of Adecatumumab and Docetaxel
2. Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO
3. Micromet, Inc. to Host Conference Call and Webcast to Report First Quarter 2009 Financial Results on May 6, 2009
4. Micromet Presents Data at AACR Meeting Showing Elimination of Colorectal Cancer Stem Cells by BiTE Antibody MT110
5. Micromet to Present at the Future Leaders in the Biotech Industry Conference on April 2, 2009
6. Micromet Adds Sir Walter Bodmer and Bernard Fox to Its Advisory Panel for BiTE Antibody Therapeutics
7. Micromet to Present Six Posters on Progress of BiTE Antibodies at the Annual Meeting of American Association for Cancer Research
8. Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008
9. Micromet to Present at the Cowen Health Care Conference on March 17, 2009
10. Micromet Adds Former Head of Roche Oncology Kapil Dhingra, MD to Board of Directors
11. Micromet to Present at the BIO CEO and Investor Conference on February 10, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 This webinar ... on nonclinical and clinical safety assessment in biosimilars. ... guide a path for biosimilar drug development, however ... of biosimilarity with regards to quality, safety and ... of biosimilar drug development and registration, development strategies ...
(Date:1/15/2014)... NC (PRWEB) January 15, 2014 ... an enhancement to its Online Web Portal for Life ... now have the ability to specify the subject matter ... nearly 50 life science sub-domains. This will help reduce ... and scientific fields, and decrease the likelihood of error. ...
(Date:1/14/2014)... Doylestown, PA (PRWEB) January 14, 2014 ... – 11 p.m. , Location: Warrington Country Club, 1360 ... Hepatitis B Foundation, the only national nonprofit organization solely ... improving the quality of life for those affected worldwide, ... 11 at Warrington Country Club in Warrington, Pa. ...
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... initiated coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua ... and marketing proprietary products to serve the wound ... , In late 2012, Alliqua was restructured ... launched the company’s new strategy to become a ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... in Dane County saw its largest single-year job increase in ... to the 2007 Greater Madison Area Directory of High-Tech Companies ... , Purchase online The 21st annual ... in 12 industry clusters. They reported more than $5.5 billion ...
... you, it was in the middle of a week's trip to ... a new trade office in that country. The initial part of ... ancient capitol of Agra (home to the Taj Mahal among other ... part of the trip. I promised to share with you both ...
... knows the Bay Area and Silicon Valley very well, but ... proposition to building a thriving technology industry, and it starts ... and CEO of the Information Technology Association of Wisconsin ... has been serving in place of former chief executive Jim ...
Cached Biology Technology:Directory shows high-tech growth spurt in Dane Co. 2Directory shows high-tech growth spurt in Dane Co. 3Directory shows high-tech growth spurt in Dane Co. 4A Midwest passage to India, Part II 2A Midwest passage to India, Part II 3A Midwest passage to India, Part II 4A Midwest passage to India, Part II 5A Midwest passage to India, Part II 6A Midwest passage to India, Part II 7A Midwest passage to India, Part II 8Wisconsin IT association names Gee president, CEO 2
(Date:4/15/2014)... research into parasites of cuttlefish, squid and octopus ... cycles, and shown how they may help in ... Sarah Catalano has described 10 new parasite species− ... of cephalopods (cuttlefish, squid and octopus). They ... described from Australian waters. , "Although dicyemid ...
(Date:4/14/2014)... forest moths in Finnish Lapland suggests that scientists may ... and plants because much of the harm is hidden ... moth species and found that 90 percent of them ... from 1978 to 2009. During that time, average annual ... and winter precipitation increased as well. , "You see ...
(Date:4/14/2014)... the greenhouse gas methane were found above shale gas ... an important emissions source, according to a study jointly ... have implications for the evaluation of the environmental impacts ... one of only a few to use a so-called ... the air above wells, identified seven individual well pads ...
Breaking Biology News(10 mins):Bizarre parasite may provide cuttlefish clues 2Moth study suggests hidden climate change impacts 2Moth study suggests hidden climate change impacts 3'Problem wells' source of greenhouse gas at unexpected stage of natural gas production 2
... major component of green tea could prove the perfect ... to a bacterial infection. In a new laboratory study, ... Research, and his colleagues have been studying the therapeutic ... a fatal immune response that kills 225,000 Americans every ...
... innovative new rheumatoid arthritis drug Actemra (tocilizumab) has ... symptoms of rheumatoid arthritis (RA) in patients who ... disease modifying agents (DMARDs). Exciting new data from ... breaker, at the American College of Rheumatology (ACR) ...
... LOS ANGELES (November 7, 2007) FIJI Water, one ... in the world, announced a Sustainable Growth Initiative today ... 2008. To achieve this, FIJI Water will account ... its products and then, through a combination of meaningful ...
Cached Biology News:In the laboratory, green tea proves a powerful medicine against severe sepsis 2New Actemra data shows significant benefit for patients suffering from rheumatoid arthritis 2New Actemra data shows significant benefit for patients suffering from rheumatoid arthritis 3FIJI Water announces sustainable growth initiative with commitment to help mitigate climate change 2FIJI Water announces sustainable growth initiative with commitment to help mitigate climate change 3FIJI Water announces sustainable growth initiative with commitment to help mitigate climate change 4FIJI Water announces sustainable growth initiative with commitment to help mitigate climate change 5
Anti-ACTH Immunogen: Porcine ACTH conjugated to BSA. Available Date: 38566...
Goat polyclonal to BACE1 ( Abpromise for all tested applications). entrezGeneID: 23621 SwissProtID: P56817...
... Immunogen: Peptide ... encompassing the human, mouse, and ... Accession Number: NM_000314 ... Routinely evaluated by immunoblot. ...
Mouse monoclonal [MN-8C4] to zona radiata ( Abpromise for all tested applications). Antigen: Purified eggshell proteins (zona radiata proteins and small amounts of zona pellucida proteins) from ...
Biology Products: